Jump to content

Surly #Stonks


Wally Fairway

Recommended Posts

19 minutes ago, Harrison Stafford said:

 

I dont think people understand the importance of IBRX’s news last week regarding treating lung cancer. With the trial results in 2nd line and 3rd line lung cancer and Anktiva being an approved drug in bladder cancer, a label expansion is not going to be nearly as difficult as a new set of trials (Phase 1, Phase 2, Phase 3).  In fact, The FDA could fast track this treatment.  IBRX + 2.35 to $9.70.

The talk of the long term response they see is also promising. Mentions of it having potential for being a vaccine like treatment as well because of it.

  • Hook 'Em 1
Link to comment
Share on other sites

GERN earnings call on 5/2, coverage started today by Cowen with a buy rating and target of $10.

Quote

Analysts at TD Cowen began coverage on shares of Geron (NASDAQ:GERN - Get Free Report) in a note issued to investors on Monday, Briefing.com reports. The firm set a "buy" rating and a $10.00 price target on the biopharmaceutical company's stock. TD Cowen's price target would suggest a potential upside of 163.85% from the stock's previous close.

 

https://www.marketbeat.com/instant-alerts/nasdaq-gern-initiated-coverage-2024-04-29/

 

  • Hook 'Em 1
Link to comment
Share on other sites

1 hour ago, BurdineBandit said:

Sorry for the weird derail, but I think it's a hell of a coincidence that my older sister told me that her bladder cancer has come back yesterday, and this thing popped today. She'll be receiving immunotherapy treatments again for the next year. Her last round ~2 years ago cleared her, but they expected it to come back eventually, and it did this month. I have no idea what Anktiva does, or in what situations, but now I feel like I gotta ask her questions to see if this would be more of a help for her if/when it hits the market.

IBRX is supposed to begin shipping Anktiva May 6th.  Anktiva will become the standard of care treating bladder cancer. You mos def want to make your sister aware of this drug!

  • Hook 'Em 1
Link to comment
Share on other sites

Was trying to get an order in to buy 100 Jan 25 $10 calls on IBRX on Thursday afternoon, but my deposit wasn't cleared for options/margin trading until late friday.  Could have had those for $.35/.   4x return (8x at the open this morning).  I may speed up the timeline on it from Jan to June.  

Link to comment
Share on other sites

On 4/26/2024 at 3:22 PM, victory88 said:

Double, I need this bitch to go to $32 to break even lmao

As of the April 15th report, 54.838 million shares of IBRX were sold short. That’s up about 75,000 shares from the end of March. If they can get a squeeze going, IBRX will be something to behold.

  • Hook 'Em 1
Link to comment
Share on other sites

27 minutes ago, Harrison Stafford said:

As of the April 15th report, 54.838 million shares of IBRX were sold short. That’s up about 75,000 shares from the end of March. If they can get a squeeze going, IBRX will be something to behold.

Yeah, the 5/9 and especially 5/24 report should be quite telling here as to the mood of the shorts.

Link to comment
Share on other sites

Short term, there’s a distinct possibility of a seismic short squeeze to propel the sp of IBRX much higher.  Long term, Patrick Soon-Shiong sells IBRX to Merck, BMS, or Roche in 2024, 2025, or 2026 at a value reflecting a sp of $50+.  They all have patent cliffs coming real soon with Keytruda, Opdivo, and Tecentriq, respectively.  Now, you can add Anktiva to their drug to extend the benefit and extending the runways of their drugs until Anktiva’s patent cliff in 2035.  Plus, the only way Patrick Soon-Shiong maximizes Anktiva is by selling to Big Pharma enabling sales in China, Japan, and the rest of world, not just the handful of markets they had on that slide in last Friday’s presentation.  And Patrick Soon-Shiong is 71 years old.  Would you like to try and put together a global sales force at 71?

  • Hook 'Em 3
  • Drool 1
Link to comment
Share on other sites

Need some technical help here…

I’ve held 150 shares of MMM for way too long and want to sell.  In the mean time they spun off their healthcare side and now I have 44 shares of Solventum (SOLV) that I want to dump as well.

So for tax purposes, how do I put down the cost basis for those 44 shares?

 

Link to comment
Share on other sites

20 hours ago, Superhero said:

Need some technical help here…

I’ve held 150 shares of MMM for way too long and want to sell.  In the mean time they spun off their healthcare side and now I have 44 shares of Solventum (SOLV) that I want to dump as well.

So for tax purposes, how do I put down the cost basis for those 44 shares?

 

Per 3Ms filing on their investor relations site, you will allocate 15.52% of your original tax basis in the 3M shares to your SOLV shares received in the spinoff.

I think your brokerage may automatically do this for you (assuming they have the original basis info).

  • Hook 'Em 1
Link to comment
Share on other sites

Posted (edited)
On 5/1/2024 at 1:50 PM, Harrison Stafford said:

Short term, there’s a distinct possibility of a seismic short squeeze to propel the sp of IBRX much higher.  Long term, Patrick Soon-Shiong sells IBRX to Merck, BMS, or Roche in 2024, 2025, or 2026 at a value reflecting a sp of $50+.  They all have patent cliffs coming real soon with Keytruda, Opdivo, and Tecentriq, respectively.  Now, you can add Anktiva to their drug to extend the benefit and extending the runways of their drugs until Anktiva’s patent cliff in 2035.  Plus, the only way Patrick Soon-Shiong maximizes Anktiva is by selling to Big Pharma enabling sales in China, Japan, and the rest of world, not just the handful of markets they had on that slide in last Friday’s presentation.  And Patrick Soon-Shiong is 71 years old.  Would you like to try and put together a global sales force at 71?

I could be wrong.  If PSS doesn’t sell the company, in that case, we’re on the ground floor of the next big pharma company.  

Edited by Harrison Stafford
  • Hook 'Em 1
Link to comment
Share on other sites

7 minutes ago, Harrison Stafford said:

I could be wrong.  If PSS doesn’t sell the company, in that case, we’re on the ground floor of the next big pharma company.  

I'm back in the green on my 500 shares, next stop 🚀🚀🚀

  • Hook 'Em 1
Link to comment
Share on other sites

17 hours ago, hornmpa96 said:

Per 3Ms filing on their investor relations site, you will allocate 15.52% of your original tax basis in the 3M shares to your SOLV shares received in the spinoff.

I think your brokerage may automatically do this for you (assuming they have the original basis info).

Yeah, thats how it worked for me when I received 500 shares in a spinoff last year. If I click on the tax lots for spinoff entity, it shows 4 separate and different cost basis amounts tied to the 4 dates that I accumulated shares. Etrade did the work for me. 

  • Hook 'Em 1
Link to comment
Share on other sites

18 hours ago, hornmpa96 said:

Per 3Ms filing on their investor relations site, you will allocate 15.52% of your original tax basis in the 3M shares to your SOLV shares received in the spinoff.

I think your brokerage may automatically do this for you (assuming they have the original basis info).

 

1 hour ago, Blotto said:

Yeah, thats how it worked for me when I received 500 shares in a spinoff last year. If I click on the tax lots for spinoff entity, it shows 4 separate and different cost basis amounts tied to the 4 dates that I accumulated shares. Etrade did the work for me. 

 Thank you gents.

 I switched to Chase in 2019, and don’t exactly remember when I bought MMM.  What I do know is how many shares I initially bought and the cost per share.

I’ll see if Chase has the information from when I moved my stocks and funds over. Thanks again.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.



×
×
  • Create New...